{"entity":{"id":"nct06532617","kind":"trial","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of cadonilimab in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, now recruiting.","summary":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06532617 by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 30 participants, started 2024-09-19 and due to reach its primary completion in 2026-08-01. Interventions recorded: Cadonilimab+S-1or Capecitabine. Conditions listed: Pancreatic Neoplasms. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: \"* Histopathologically confirmed pancreatic ductal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06532617","url":"https://clinicaltrials.gov/study/NCT06532617"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cadonilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06532617","phase":"2","setting":"A Single-arm Phase II Clinical Study of Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Patients With Advanced Pancreatic Cancer","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","participation":[{"nct":"NCT06532617","source":"https://clinicaltrials.gov/study/NCT06532617","fetchedAt":"2026-10-07T16:54:46.480Z","studySha256":"e97fc3f344f7bb1a0f097e863c737d39a03d086ac0efc549887226fc2c149cd9","overallStatus":"RECRUITING","lastUpdatePosted":"2025-05-14","leadSponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-09-19","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06532617/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}